

Key: &gt;&gt;&gt; ... marks correct (expected) result

&gt; ... marks conditionally correct (acceptable) result

± ... marks the result not evaluated

N ... number of the results

Nrel ... relative number of the results

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
--------	-------	---	--------	------------------

**&nbsp;****(451) AMA**

A	(1) Fluorescent methods	>>>	49	Negative	94 %
			1	Positive	1,9 %
	(5) Immunoblotting	>>>	1	Negative	1,9 %
			1	Positive	1,9 %
Total per sample: n = 52		Success: 96 %			
B	(1) Fluorescent methods		1	Negative	1,9 %
		>>>	49	Positive	94 %
	(5) Immunoblotting	>>>	2	Positive	3,8 %
Total per sample: n = 52		Success: 98 %			
Total success: 96 %					

**(452) anti-LKM**

A	(1) Fluorescent methods		1	Negative	2,1 %
		>>>	42	Positive	89 %
	(5) Immunoblotting	>>>	4	Positive	8,5 %
Total per sample: n = 47		Success: 98 %			
B	(1) Fluorescent methods	>>>	43	Negative	91 %
	(5) Immunoblotting	>>>	4	Negative	8,5 %
Total per sample: n = 47		Success: 100 %			
Total success: 98 %					

**(453) SMA**

A	(1) Fluorescent methods	>>>	51	Negative	94 %
	(5) Immunoblotting	>>>	3	Negative	5,6 %
Total per sample: n = 54		Success: 100 %			
B	(1) Fluorescent methods	>>>	51	Negative	94 %
	(5) Immunoblotting	>>>	3	Negative	5,6 %
Total per sample: n = 54		Success: 100 %			
Total success: 100 %					

**(455) anti-LKM1**

A	(1) Fluorescent methods	>>>	1	Positive	1,9 %
	(2) EIA methods	>>>	13	Positive	24 %
(5) Immunoblotting	>>>	40	Positive	74 %	
Total per sample: n = 54		Success: 100 %			
B	(1) Fluorescent methods	>>>	1	Negative	1,9 %
	(2) EIA methods	>>>	13	Negative	24 %
	(5) Immunoblotting	>>>	39	Negative	72 %
Total per sample: n = 54		Success: 98 %	1	Inconclusive result (borderline)	1,9 %
Total success: 98 %					

**(456) AMA-M2**

A	(2) EIA methods	>>>	12	Negative	22 %
	(5) Immunoblotting	>>>	42	Negative	76 %
Total per sample: n = 55		Success: 98 %	1	Positive	1,8 %
B	(2) EIA methods	>>>	12	Positive	22 %
	(5) Immunoblotting	>>>	43	Positive	78 %
Total per sample: n = 55		Success: 100 %			
Total success: 98 %					

**(454) anti-gp210**

A	(0) Not specified	>>>	1	Negative	2,7 %
	(1) Fluorescent methods	>>>	2	Negative	5,4 %
	(2) EIA methods	>>>	1	Negative	2,7 %
(5) Immunoblotting	>>>	33	Negative	89 %	
	Total per sample: n = 37		Success: 100 %		
B	(0) Not specified	>>>	1	Positive	2,7 %
	(1) Fluorescent methods		1	Negative	2,7 %
		>>>	1	Positive	2,7 %
	(2) EIA methods	>>>	1	Positive	2,7 %
	(5) Immunoblotting		1	Negative	2,7 %
>>>		32	Positive	86 %	
Total per sample: n = 37		Success: 95 %			
Total success: 95 %					

## Summary statistics - qualitative results

(Groups: measurement principle)

## EQA round: AIH2/18 - Autoimmune Liver Diseases

Dead line: 21.09.2018

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(457) anti-LC-1</b>				
A	(0) Not specified	>>>	1 Negative	2,1 %
	(2) EIA methods	>>>	3 Negative	6,4 %
	(5) Immunoblotting	>>>	43 Negative	91 %
----- Total per sample: n = 47		-----	Success: 100 %	-----
B	(0) Not specified	>>>	1 Negative	2,1 %
	(2) EIA methods	>>>	3 Negative	6,4 %
	(5) Immunoblotting	>>>	43 Negative	91 %
----- Total per sample: n = 47		-----	Success: 100 %	-----
Total success: 100 %				

**(458) anti-SLA**

A	(0) Not specified	>>>	1 Negative	2,0 %
	(2) EIA methods	>>>	5 Negative	10 %
	(5) Immunoblotting	>>>	43 Negative	88 %
----- Total per sample: n = 49		-----	Success: 100 %	-----
B	(0) Not specified	>>>	1 Negative	2,0 %
	(2) EIA methods	>>>	5 Negative	10 %
	(5) Immunoblotting	>>>	43 Negative	88 %
----- Total per sample: n = 49		-----	Success: 100 %	-----
Total success: 100 %				

**(459) anti-sp100**

A	(1) Fluorescent methods	>>>	2 Negative	5,4 %
	(2) EIA methods	>>>	1 Negative	2,7 %
	(5) Immunoblotting	>>>	34 Negative	92 %
----- Total per sample: n = 37		-----	Success: 100 %	-----
B	(1) Fluorescent methods	>>>	2 Negative	5,4 %
	(2) EIA methods	>>>	1 Negative	2,7 %
	(5) Immunoblotting	>>>	34 Negative	92 %
----- Total per sample: n = 37		-----	Success: 100 %	-----
Total success: 100 %				

st\_kl

End of report

Printed: 02.10.2018